From the H. Lee Moffitt Cancer Center and Research Institute, Department of Molecular Medicine and Department of Oncologic Sciences, University of South Florida, Tampa, Florida 33612.
the Laboratory of Molecular Growth Regulation, NICHD, National Institutes of Health, Bethesda, Maryland 20892.
J Biol Chem. 2011 Mar 11;286(10):7893-7904. doi: 10.1074/jbc.M110.165431. Epub 2011 Jan 7.
Dendritic cells (DCs) are key mediators of immune function through robust and tightly regulated presentation of antigen in the context of the MHC Class II. MHC Class II expression is controlled by the transactivator CIITA. CIITA expression in conventional DCs is uniquely dependent on an uncharacterized myeloid cell-specific promoter, CIITApI. We now identify in vivo the promoter structure and factors regulating CIITApI. In immature DCs transcription requires binding of PU.1, IRF8, NFκB, and Sp1 to the promoter. PU.1 binds independently at one site and in a required heterodimer with IRF8 at a composite element. DCs from IRF8-null mice have an unoccupied CIITApI promoter that can be rescued by reconstitution with IRF8 in vitro. Furthermore, mutation of either PU.1 site or the IFR8 site inhibits transcriptional activation. In vivo footprinting and chromatin immunoprecipitation reveals that DC maturation induces complete disassociation of the bound activators paralleled by recruitment of PRDM1/Blimp-1 to the promoter. PRDM1 is a transcriptional repressor with essential roles in B cells, T cells, NK cells, and DCs. We show that PRDM1 co-repressors, G9a and HDAC2, are recruited to CIITApI, leading to a loss of histone acetylation and acquisition of histone H3K9 dimethylation and heterochromatin protein 1γ (HP1γ). PRDM1 binding also blocks IRF8-mediated activation dependent on the PU.1/IRF composite element. Together these findings reveal the mechanisms regulating CIITA and, thus, antigen presentation in DCs, demonstrating that PRDM1 and IRF8/PU.1 counter-regulate expression. The activity of PRDM1 in silencing all three cell type-specific CIITA promoters places it as a central regulator of antigen presentation.
树突状细胞(DCs)通过在 MHC II 类背景下强有力且严格调控的抗原呈递来充当免疫功能的关键介质。MHC II 类的表达受转录激活因子 CIITA 调控。经典 DCs 中的 CIITA 表达依赖于一个尚未明确的髓系细胞特异性启动子,即 CIITApI。我们现在鉴定出了体内调控 CIITApI 的启动子结构和调控因子。在未成熟的 DCs 中,转录需要 PU.1、IRF8、NFκB 和 Sp1 结合到启动子上。PU.1 独立地在一个位点结合,并与 IRF8 在一个复合元件上形成必需的异二聚体。IRF8 缺失型小鼠的 DCs 具有未被占据的 CIITApI 启动子,该启动子可以通过体外重建 IRF8 来恢复。此外,PU.1 位点或 IFR8 位点的突变会抑制转录激活。体内足迹分析和染色质免疫沉淀揭示,DC 成熟会诱导结合的激活子完全解聚,同时募集 PRDM1/Blimp-1 到启动子上。PRDM1 是一种转录抑制因子,在 B 细胞、T 细胞、NK 细胞和 DC 中具有重要作用。我们发现,PRDM1 的共抑制因子 G9a 和 HDAC2 被募集到 CIITApI,导致组蛋白乙酰化丢失和组蛋白 H3K9 二甲基化以及异染色质蛋白 1γ(HP1γ)获得。PRDM1 结合还会阻止依赖于 PU.1/IRF 复合元件的 IRF8 介导的激活。这些发现揭示了调控 CIITA 从而调控 DC 中抗原呈递的机制,表明 PRDM1 和 IRF8/PU.1 相互拮抗来调控表达。PRDM1 对所有三种细胞类型特异性 CIITA 启动子的沉默活性使其成为抗原呈递的中央调控因子。